Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Muggia

Showing results (381-390 of 424) with videos related to

Pageof 43
Sort By:
Cancer Treatment Reports|March 1, 1986
Cisplatin and vinblastine chemotherapy for metastatic non-small cell carcinoma followed by irradiation in patients with regional diseaseR H Blum, J Cooper, A M Schmidt, et al.
Anti-Cancer Drugs|October 24, 2002
Phase I and pharmacologic study of i.p. 9-aminocamptothecin given as six fractions over 14 daysFranco M Muggia, Leonard Liebes, Maitreyee Hazarika, et al.
Molecular Cancer Therapeutics|December 21, 2002
PS-341, a novel proteasome inhibitor, induces Bcl-2 phosphorylation and cleavage in association with G2-M phase arrest and apoptosisYi-He Ling, Leonard Liebes, Bruce Ng, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 1, 2004
Biweekly 72-hour 9-aminocamptothecin infusion as second-line therapy for ovarian carcinoma: phase II study of the New York Gynecologic Oncology Group and the Eastern Cooperative Oncology GroupHoward Hochster, Elizabeth R Plimack, Carolyn D Runowicz, et al.
Gynecologic Oncology|September 15, 2010
Erlotinib added to carboplatin and paclitaxel as first-line treatment of ovarian cancer: a phase II study based on surgical reassessmentStephanie V Blank, Paul Christos, John P Curtin, et al.
Cancer|January 10, 2001
Treatment of patients with ovarian carcinoma with pegylated liposomal doxorubicin: analysis of toxicities and predictors of outcomeT Safra, S Groshen, S Jeffers, et al.
Cancer Research|April 1, 1989
Noninvasive monitoring of drug biodistribution and metabolism: studies with intraarterial Pt-195m-cisplatin in humansJ Shani, J Bertram, C Russell, et al.
Journal of the National Cancer Institute|January 17, 1990
Selection of cancer chemotherapy for a patient by an in vitro assay versus a clinicianD D Von Hoff, J F Sandbach, G M Clark, et al.
The Journal of Urology|June 1, 1991
Staging relationships and outcome in early stage testicular cancer: a report from the Testicular Cancer Intergroup StudyD G McLeod, R B Weiss, D M Stablein, et al.
American Journal of Clinical Oncology|February 24, 2001
Phase I trial of paclitaxel and etoposide for recurrent ovarian carcinoma: a Gynecologic Oncology Group StudyG F Fleming, B J Roth, S D Baker, et al.
Pageof 43

Showing results (381-390 of 424) with videos related to

Sort By:
Pageof 43
Cancer Treatment Reports|March 1, 1986
Cisplatin and vinblastine chemotherapy for metastatic non-small cell carcinoma followed by irradiation in patients with regional diseaseR H Blum, J Cooper, A M Schmidt, et al.
Anti-Cancer Drugs|October 24, 2002
Phase I and pharmacologic study of i.p. 9-aminocamptothecin given as six fractions over 14 daysFranco M Muggia, Leonard Liebes, Maitreyee Hazarika, et al.
Molecular Cancer Therapeutics|December 21, 2002
PS-341, a novel proteasome inhibitor, induces Bcl-2 phosphorylation and cleavage in association with G2-M phase arrest and apoptosisYi-He Ling, Leonard Liebes, Bruce Ng, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 1, 2004
Biweekly 72-hour 9-aminocamptothecin infusion as second-line therapy for ovarian carcinoma: phase II study of the New York Gynecologic Oncology Group and the Eastern Cooperative Oncology GroupHoward Hochster, Elizabeth R Plimack, Carolyn D Runowicz, et al.
Gynecologic Oncology|September 15, 2010
Erlotinib added to carboplatin and paclitaxel as first-line treatment of ovarian cancer: a phase II study based on surgical reassessmentStephanie V Blank, Paul Christos, John P Curtin, et al.
Cancer|January 10, 2001
Treatment of patients with ovarian carcinoma with pegylated liposomal doxorubicin: analysis of toxicities and predictors of outcomeT Safra, S Groshen, S Jeffers, et al.
Cancer Research|April 1, 1989
Noninvasive monitoring of drug biodistribution and metabolism: studies with intraarterial Pt-195m-cisplatin in humansJ Shani, J Bertram, C Russell, et al.
Journal of the National Cancer Institute|January 17, 1990
Selection of cancer chemotherapy for a patient by an in vitro assay versus a clinicianD D Von Hoff, J F Sandbach, G M Clark, et al.
The Journal of Urology|June 1, 1991
Staging relationships and outcome in early stage testicular cancer: a report from the Testicular Cancer Intergroup StudyD G McLeod, R B Weiss, D M Stablein, et al.
American Journal of Clinical Oncology|February 24, 2001
Phase I trial of paclitaxel and etoposide for recurrent ovarian carcinoma: a Gynecologic Oncology Group StudyG F Fleming, B J Roth, S D Baker, et al.
Pageof 43